Latest Information Update: 25 Jun 2003
At a glance
- Originator Ajinomoto
- Class Antibacterials
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-positive infections; Mycoses
Most Recent Events
- 13 Nov 2000 New profile
- 13 Nov 2000 Preclinical development for Gram-positive infections in Japan (Unknown route)
- 13 Nov 2000 Preclinical development for Mycoses in Japan (Unknown route)